[A19-51] Apalutamide (prostate cancer) - Addendum to Commission A19-09
Last updated 01.08.2019
Project no.:
A19-51
Commission:
Commission awarded on 12.06.2019 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Indication:
Adults with non-metastatic castration-resistant prostate cancer who are at high risk of developing metastases
Result of dossier assessment:
Conclusion of dossier assessment A19-09 unchanged
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A19-09 | Apalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2019-08-01 A G-BA decision was published.